The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
A multi-site project, called \u2018What\u2019s the STORY?\u2019 has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research\u2019s (NIHR) Urgent Public Health Response.
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still.
A new exhibition tells the story of Oxford\u2019s role in the fight against typhoid, from pioneering efforts to eliminate typhoid in the era of Lewis Carroll\u2019s Alice in Wonderland to game-changing present-day vaccine trials.
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
It\u2019s very exciting to see that the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine schedule is being used in a large-scale study in the Democratic Republic of Congo. This is an important step towards having multiple vaccine strategies available to fight this dreadful illness, as is the recent application for marketing authorisation of this schedule by the European Medicines Agency.
For most people living in the United States and Europe, typhoid is a distant memory, a ghost of a disease from another time. But typhoid never disappeared. For many people living in low- and middle-income countries, typhoid is endemic and an all too common risk faced predominately by children.
The emergence of untreatable strains of typhoid threatens a new global health emergency that requires urgent collective action, argue experts from the Oxford Martin School in the journal Clinical Infectious Diseases today.
Following the publication of figures showing UK childhood vaccination rates have fallen for the fifth year in a row, researchers from OVG and the Oxford Martin Programme on Collective Responsibility for Infectious Disease discuss possible responses.
Salmonella Typhi bacteria can invade the intestines and blood and lead to a disease called typhoid fever \u2013 a disease that affects around 11 million people each year globally.
We recently worked with Mediaplanet on the 2019 Health Awareness: Value of Vaccines campaign. The campaign features exclusive content from key thought leaders and industry voices about the critical importance of full immunisation throughout life.
Dr Samantha Vanderslott (Oxford Vaccine Group), Dr Eleanor Draeger (sexual health expert and medical writer), and Professor Beate Kampmann (London School of Hygiene and Tropical Medicine) debate compulsory vaccination. Presented by Philippa Thomas on BBC World service.
Drs Samantha Vanderslott and Claas Kirchhelle introduce their typhoid history research and 'Alice in Typhoidland' public engagement project. This work delves into the history of typhoid in Oxford and highlights why typhoid is still a major global health problem needing both water, sanitation, and hygiene (WASH) interventions alongside vaccines.
![](\"https://www.ovg.ox.ac.uk/news/landmark-partnership-announced-for-development-of-covid-19-vaccine/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n